GLP-1 RA drugs, while generally considered effective and safe for the treatment of T2D and obesity, are associated with certain risks and side effects, as documented in the literature which must not be completely overlooked. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.